6 news items
The Analyst Landscape: 4 Takes On Bio-Rad Laboratories
BIO
8 May 24
$484.00
Key Insights:
Action Taken: In response to dynamic market conditions
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
AZN
BIO
CELC
3 May 24
confirmed response rate, a 50% improvement in median progression-free survival, and a hazard ratio of 0.29 compared to the paclitaxel alone control
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
AZN
BIO
CELC
3 May 24
confirmed response rate, a 50% improvement in median progression-free survival, and a hazard ratio of 0.29 compared to the paclitaxel alone control
Bio-Rad Announces Life Science Group Management Changes
BIO
26 Apr 24
.
For the past two years, James Barry has been responsible for Bio-Rad's global manufacturing operations including quality, planning
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
BIO
OCX
11 Apr 24
that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring
uvz9s40lg85bkoav
BIO
20 Mar 24
Financial Officer responsible for all finance-related functions supporting the company's global operations since 2018. Prior to Benchmark, he held Chief
- Prev
- 1
- Next